Dermatomyositis and polymyositis (myositis) trials in Poland

In Poland 13 Also abroad 124

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Warsaw
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 3Not yet taking people in Poland
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Bialystok, Bydgoszcz, Katowice
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 3Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Bydgoszcz, Lodz, Szczecin
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 1Not yet taking people in Poland
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Bydgoszcz, Krakow, Poznan
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Cracow, Lodz, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
84 worldwide
Run by
AstraZeneca AB
See details and how to join2023-504022-19-01
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Bialystok, Krakow, Lodz, Poznan, Warsaw, Wroclaw
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Bialystok, Cracow, Poznan, Warsaw
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 3Taking people
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Where
Bialystok, Cracow, Poznan, Warsaw
Age
18 years and over
People
211 worldwide
Run by
Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bydgoszcz, Lodz, Warsaw
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Warsaw
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Warsaw
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Bytom, Gdansk, Gliwice, Lodz
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Cracow, Poznan, Warsaw
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00